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Themolecular processes that contribute to degenerative diseases are not well understood. Recent
observations suggest that some degenerative diseases are promoted by the accumulation of
nuclear or cytoplasmic RNA-protein (RNP) aggregates, which can be related to endogenous RNP
granules. RNP aggregates arise commonly in degenerative diseases because RNA-binding pro-
teins commonly self-assemble, in part through prion-like domains, which can form self-propagating
amyloids. RNP aggregates may be toxic due to multiple perturbations of posttranscriptional
control, thereby disrupting the normal ‘‘ribostasis’’ of the cell. This suggests that understanding
and modulating RNP assembly or clearance may be effective approaches to developing therapies
for these diseases.Introduction
Degenerative diseases are a poorly understood and largely
untreatable set of pathologies that take a heavy toll in disability
and death and have far-reaching socioeconomic impacts.
Illuminating the molecular causes of degenerative diseases to
inform therapeutic strategies is an important area of research.
Over the past decade, several observations have highlighted
important connections between protein aggregation, RNA
biology, and a subset of degenerative diseases (Table 1). A
conspicuous feature of some degenerative diseases, particularly
neurodegenerative diseases, is cytoplasmic or nuclear aggre-
gates of RNA-binding proteins and/or RNA. For example, redis-
tribution of RNA-binding proteins, most notably TDP-43, from
the nucleus to cytoplasmic inclusions is a hallmark pathological
feature of most sporadic and familial forms of amyotrophic
lateral sclerosis (ALS) and frontotemporal lobar degeneration
with ubiquitin-positive inclusions (FTLD-U) and is also present
in a subset of other neurodegenerative diseases (Chen-Plotkin
et al., 2010).
Toxic RNAs can also cause pathologies. A mutant RNA arising
from a hexanucleotide expansion in the C9ORF72 gene leads to
that RNA’s accumulation in nuclear foci and underlies some
cases of ALS (DeJesus-Hernandez et al., 2011; Renton et al.,
2011). Similarly, a relatively short CGG expansion in the fragile
X gene (FMR1) leads to a toxic RNA that also accumulates in
nuclear foci and causes a late onset neurodegenerative disorder
termed fragile X tremor ataxia syndrome (FXTAS; Hagerman and
Hagerman [2004]).
RNP aggregates are not limited to neurodegeneration. For
example, myotonic dystrophy types 1 and 2 are caused by
microsatellite expansions in noncoding regions of the RNAs
encoding DMPK and ZNF9, respectively. The pathology inboth of these disorders is characterized by nuclear RNP aggre-
gates that sequester splicing factors (Fardaei et al., 2002; Miller
et al., 2000), and Welander distal myopathy is caused by a
mutation in the RNA-binding protein TIA1, with accompanying
cytosolic inclusion pathology (Hackman et al., 2012; Klar et al.,
2013).
Here, we present a mechanistic framework for RNP inclusion
disease, which is based on the premise that RNP inclusions
seen in (neuro)degenerative conditions are indicative of and arise
from pathological changes in endogenous cellular pathways for
RNP assembly and clearance. We suggest that the prevalence
of such RNP inclusion diseases arises from the fact that RNPs
normally form large RNP assemblies and therefore are poised
for pathogenicity. These principles are highlighted in a model
for how specific forms of amyotrophic lateral sclerosis (ALS),
frontotemporal lobar degeneration (FTLD), and multisystem
proteinopathy (MSP) may originate from altered assembly or
clearance of stress granules, a well-studied class of cytoplasmic
RNP granule. Shared features of RNP assembly and misfolded
protein handling pathways, such as the involvement of HSP70
and autophagy, may explain some overlap between mRNP-
inclusion andmisfolded protein disease pathologies. We present
an altered ribostasis model to account for cell loss in RNP inclu-
sion diseases and discuss how understanding of endogenous
RNP regulation may inform and instruct therapeutic strategies.
Pathological RNP Aggregates Are Related to
Endogenous Assemblies
An emerging theme is that the RNP inclusions seen in pathol-
ogies are related to endogenous RNP granules that are part of
the normal metabolism of eukaryotic messenger RNAs (mRNAs)
and could reflect a disturbance in the assembly, disassembly,Cell 154, August 15, 2013 ª2013 Elsevier Inc. 727
Table 1. Protein-Folding and RNP Diseases
Diseases Mutated Protein/Gene Details and References
Protein-Folding Diseases: Caused by Point Mutations that Destabilize Protein Domains
Alzheimer’s, Parkinson’s APP a-synuclein (A53T, A30P,
and E46K mutations)
Schellenberg and Montine, 2012; Li et al., 2001;
Zarranz et al., 2004
ALS (a) SOD1 Rosen et al., 1993
Myofibrillar myopathy myotilin, desmin Baloh, 2011; Olive´ et al., 2009
RNP Diseases: Caused by Mutations in RNAs or RNA-Binding Proteins
Spinocerebellar ataxias (SCA1–3, 6, 7, 17) polyglutamine expansions in
respective RNA-binding proteins
PolyQ expansions enhance homotypic and
heterotypic aggregation of complexes;
De Los Rios et al., 2012; Ross and Poirier, 2004
SCA-8 CUG expansion in a noncoding RNA Daughters et al., 2009; Mutsuddi et al., 2004;
fly models for this are suppressed by mutations
in staufen and in two other RNA-binding proteins
SCA-10 possibly due to an aberrant, stable
intronic RNA (AUUCU expansion)
Matsuura et al., 2000; White et al., 2012
ALS (b) Atx2, TDP-43, FUS (prion-like domain
mutations), hnRNPA1, hnRNPA2B1,
VCP (mutations cause increased
granule assembly)
mutations may result in increased aggregation;
Couthouis et al., 2012; Elden et al., 2010;
Johnson et al., 2009; Johnson et al., 2010;
Kim et al., 2013; Liu-Yesucevitz et al., 2011;
Neumann et al., 2006; Sreedharan et al., 2008;
Vance et al., 2009
ALS (c) aberrant RNA Davis et al., 1997; Mankodi et al., 2001
DM1 and 2 aberrant RNA Davis et al., 1997; Mankodi et al., 2001
FXTAS aberrant RNA Hashem et al., 2009; Iwahashi et al., 2006;
Tassone et al., 2004
Laminopathies Lam-A or Lam-C mutations with
defects in RNA granule assembly
in the nucleus
Speese et al., 2012
Oculopharyngeal muscular dystrophy Polyalanine expansion in PABPN1 Brais et al., 1998
Welander distal myopathy TIA1 (prion-like domain mutation
that increases stress granule assembly)
Hackman et al., 2012
Distal myopathy (vocal cord and
pharyngeal weakness variant)
matrin-3 Senderek et al., 2009
Possibly RNP-Folding Diseases: Associated with RNP Aggregates
Huntington’s Htt P body and dendritic RNA granule protein
associated with Ago-2; Savas et al., 2010;
Savas et al., 2008
Prion disease Prp mutations increased aggregation, potentially with RNAs;
Solomon et al., 2010
Others (e.g., Alzheimer’s) sporadic forms RNA and TDP-43 frequently reported in
associated inclusions; Davidson et al., 2011;
Tremblay et al., 2011; Wilson et al., 2011or clearance of these structures (Figure 1). During transcription,
nascent mRNAs in the nucleus assemble with a set of RNA-
binding proteins (Moore, 2005). These RNA-binding proteins,
including TDP-43, hnRNPA1, hnRNPA2B1, and others involved
in neurodegenerative disease, affect pre-mRNA processing
and are transported with the mRNA to the cytosol, where they
are removed by translation-dependent and -independent
mechanisms for recycling into the nucleus (Moore, 2005). In
the cytosol, when mRNAs are not engaged in translation, they
assemble into either P bodies, which contain mRNAs, translation
repressors, components of the miRNA-silencing pathway and
the mRNA decay machinery (Parker and Sheth, 2007), or stress728 Cell 154, August 15, 2013 ª2013 Elsevier Inc.granules, which contain mRNAs associated with mRNA-binding
proteins and a subset of translation initiation factors. Stress
granules accumulate to higher levels in cells or conditions, such
as stress, in which translation initiation is limited (Anderson and
Kedersha, 2009; BuchanandParker, 2009). CytoplasmicmRNAs
exchange between polysomes, P bodies, and stress granules,
creating a dynamic cycle of mRNP exchanges that influences
the translation and degradation of mRNAs (Figure 1). Stress
granules can contain nuclear mRNA-binding proteins, suggest-
ing that, when entry into translation is compromised, nascent
mRNPs accumulate in these structures before exchange of
nuclear RNA-binding proteins (Buchan and Parker, 2009).
Figure 1. mRNP Remodeling and Aggrega-
tion in the Lifecycle of an mRNA
Transcribed RNAs form nuclear messenger ribo-
nucleoprotein particles (mRNPs). RNA-binding
proteins associated with mRNA are transported to
the cytosol, where they determine cytoplasmic
localization and translational competence of the
mRNA. mRNAs begin to assemble translation
complexes, and when this process is stalled, the
mRNPs accumulate as stress granules. mRNPs
within stress granules can return to translation
initiation and enter polysomes or can be targeted
for autophagy. Following translation, mRNAs can
exit translation and assemble a translationally
repressed mRNP that either can be degraded or
can assemble into P bodies. mRNAs within
P bodies can be subject to decapping and 50-to-30
degradation or can exchange P body compo-
nents for stress granule components to re-enter
translation. Stress granules are proposed to
undergo pathological transitions wherein loose
assemblies of prion-like domains can form irre-
versible b amyloid structures.Three observations suggest that the TDP-43-positive RNP
aggregates seen in some ALS and FTLD-U patients are related
to stress granules. First, inclusions seen in pathologies can
contain other markers of stress granules (Liu-Yesucevitz et al.,
2010; Wolozin, 2012). Second, the RNA-binding proteins that
can become pathogenic when mutated (e.g., hnRNPA1, TDP-
43, FUS, ATX2) all normally assemble into stress granules in
response to stress stimuli (Dormann et al., 2010; Guil et al.,
2006). Finally, the pathogenic alleles of several of these proteins
lead to constitutive formation of stress granules in tissue culture
cells, even in the absence of a stress response (Kim et al., 2013;
Liu-Yesucevitz et al., 2010; Wolozin, 2012).
An analogous situation may exist in diseases characterized
by aberrant accumulation of nuclear RNP aggregates, such as
myotonic muscular dystrophy types 1 and 2, FXTAS, or with
the C9ORF72-related ALS/FTD. These nuclear RNP inclusions
may be related to a number of RNA-protein assemblies that
normally form in the nucleus (Spector, 2006). One interesting
possibility is that these nuclear RNA foci are related to a special-
ized mega-RNP assembly containing lamin A, which plays a role
inmRNA export by vesicle budding through the nuclear envelope
(Speese et al., 2012). This is a particularly interesting possibility
for the RNA foci seen in FXTAS, as they are known to contain
lamins A and C (Iwahashi et al., 2006).
Cytoplasmic RNP Granules: Poised for Pathogenicity
An important point is that mRNP granules assemble through
protein-protein interactions, including interactions between
‘‘prion-like’’ domains. This was first suggested by evidenceCell 154that stress granules in mammalian cells
assemble, in part, through multimeriza-
tion of a prion-like domain in the TIA-1
protein (Gilks et al., 2004). A prion domain
in the Lsm4 protein was also shown to
be part of the assembly mechanism for
yeast P bodies (Decker et al., 2007).
Moreover, many RNA-binding proteinscontain such prion-like domains, or other low complexity do-
mains, that can mediate assembly into higher-order structures
in vivo and in vitro (Decker et al., 2007; Gilks et al., 2004; Kato
et al., 2012; Kim et al., 2013; Reijns et al., 2008); Li et al.,
2013). Thus, an emerging principle is that cytoplasmic RNP
granules such as stress granules and P bodies assemble due
to the presence of prion-like polymerization domains on many
RNA-binding proteins, and these domains reversibly assemble
and disassemble in the normal metabolism of cytoplasmic
mRNPs (Figure 2).
The high prevalence of prion-like domains in RNA-binding
proteins creates a large genetic target for pathogenic mutations
that create hyperaggregation variants with downstream toxic
effects. For example, pathogenic mutations in the prion-like do-
mains of hnRNPA1 and hnRNPA2B1 are predicted to increase
its aggregation potential, show increased aggregation in vitro,
and lead to hyperassembly of stress granules in cultured cells
(Kim et al., 2013). Similarly, expansion of a polyglutamine domain
in the Atx2 protein, which is a subclass of prion-like domains,
leads to hyperaggregation of the Atx2 proteins, which can be a
risk factor in ALS (Elden et al., 2010) and, when extreme enough,
leads to spinocerebellar ataxia 2 (Orr and Zoghbi, 2007). The role
of RNA-binding proteins with prion-like domains in degenerative
pathologies may be quite common, as 10 of the top 20 human
RNA-binding proteins predicted to have such domains have
been linked to some form of degenerative disease (Li et al.,
2013). This prevalence suggests that hyperassembly of RNP
aggregates related to stress granules may be a causative event
in disease progression., August 15, 2013 ª2013 Elsevier Inc. 729
Figure 2. Normal Stress Granule Dynamics and Possible Evolution of Pathogenic Inclusions
Cytoplasmic RNP granules such as stress granules and P bodies assemble due to the presence of prion-like polymerization domains on many RNA-binding
proteins. In the normal metabolism of cytoplasmic mRNPs, these granules reversibly assemble and disassemble, or persistent stress granules may be cleared by
autophagy, controlling the content of the translatable pool of mRNAs. We suggest that stable amyloid assemblies may be formed stochastically from normal
stress granules and, further, that mutations affecting prion-like domains or an increased number or persistence of stress granules increases the probability of this
transition. Over time, these stable, persistent mRNP assemblies could evolve into the pathological inclusions characteristic of disease and could impair ribostasis
by sequestration of RNAs or RNA-binding proteins or by altering signaling pathways.Additional evidence pointing to inappropriate stress granule
formation as being toxic comes from the analysis of the
VCP, or p97, protein. VCP is a highly conserved AAA-ATPase
that plays a role through multiple different adaptors in segre-
gating or rearranging a variety of complexes containing ubiqui-
tinated proteins (Meyer et al., 2012; Yamanaka et al., 2012).
Mutations in VCP can be causative in multisystem proteinop-
athy (MSP) and ALS and give rise to the same spectrum of
pathologies as dominant hyperaggregation mutations in
TDP-43, hnRNPA1, or hnRNPA2B1 (Dewey et al., 2012). Three
observations suggest that this overlap in pathologies is due to
a molecular overlap affecting stress granule dynamics. First,
pathogenic mutations in VCP lead to the constitutive accu-
mulation of TDP-43, hnRNPA1, hnRNPA2B1, and other stress
granule markers in cytoplasmic foci (Dewey et al., 2012).
Second, RNAi-mediated knockdown of VCP in mammalian
cells or loss-of-function mutations in the yeast ortholog
CDC48 lead to the persistence or constitutive formation of
stress granules due to defects in stress granule clearance
(Buchan et al., 2013). Finally, overexpression of VCP-harboring
disease mutations inhibits the clearance of stress granules, at
least in part by limiting their removal by autophagy (Buchan
et al., 2013).
Because the same spectrum of diseases is caused by a
variety of mutations in RNA-binding proteins that promote
RNP aggregation and/or stress granule formation, as well as
mutations in VCP/Cdc48 that reduce stress granule clearance,
a reasonable hypothesis is that hyperformation or persistence
of stress granules is an underlying causative event in these
diseases.730 Cell 154, August 15, 2013 ª2013 Elsevier Inc.A Working Model for ALS, FTLD, and MSP
The current observations suggest a working model whereby
the pathology of these diseases is driven by the assembly of
specific RNA-binding proteins into self-propagating hyperstable
amyloids (Figure 2), which form RNP aggregates and disrupt
ribostasis, eventually leading to cell death. In principle, amyloids
could form during the normal assembly of stress granules and
could be continually disassembled by cellular mechanisms
(e.g., chaperonins). However, because stress granules are
highly dynamic with rapid protein exchange rates (t1/230 s)
as measured by fluorescence recovery after photobleaching
(FRAP; Buchan and Parker, 2009) and because prion-like
domains can also form looser more reversible interactions
(Eisenberg and Jucker, 2012), we favor a model wherein
hyperstable amyloid assemblies are not part of the normal
assembly mechanisms of stress granules and instead can form
stochastically from the looser interactions between prion-like
domains that would predominate within normal stress granules.
In this view, the frequency of amyloid formation would be
affected by mutations in RNA-binding proteins that increase
the tendency to form a stable amyloid structure (Kim et al.,
2013). In addition, because amyloid initiation is a stochastic
event dependent on concentration and time (Eisenberg and
Jucker, 2012), any alteration that increases the size or persis-
tence of the high local concentration of RNA-binding proteins
in stress granules (shown in red in Figure 1), such as defects in
clearance mechanisms due to VCP mutations (Buchan et al.,
2013), is expected to yield an increased frequency of amyloid
initiation. Moreover, environmental insults that promote ALS
can be understood in this context as triggering stress granule
formation. For example, examination of the brains of boxers and
head injury patients reveals the accumulation of TDP-43 in cyto-
plasmic aggregates (King et al., 2010; McKee et al., 2010; Stern
et al., 2011), which may be remnants of trauma-induced stress
granule formation.
RNP aggregates that contain amyloid structures may no
longer be capable of being disassembled by normal mecha-
nisms and could only be cleared by autophagy. The self-perpet-
uation of such toxic assemblies might be tolerated in younger
individuals, but as autophagy declines with age, the clearance
of such assemblies would slow down until a toxic level was
reached, when disease would be triggered.
An interesting and important area of future research is the
potential role that cell-to-cell transmission of RNA-protein
aggregates plays in disease progression. This is an issue, as it
now appears that many ‘‘protein-folding’’ diseases, such as
Alzheimer’s disease, Parkinson’s disease, tauopathies, and
Huntington’s disease, can be transmitted between cells in a
‘‘prionoid’’ type of mechanism that is poorly understood (Aguzzi
and Rajendran, 2009). RNA-protein aggregates forming in
these diseases could play a similar role, either by being taken
up by neighboring cells after cell death and lysis or by specific
mechanisms that transfer material between cells. For example,
RNA and protein complexes can be secreted from cells in
exosomes (Raposo and Stoorvogel, 2013) that, if taken up by
neighboring cells, might also transfer a self-perpetuating RNA-
protein complex.
Does RNA Matter?
Several observations argue that at least part of the pathology of
these mutations involves their ability to bind RNA. First, this is
implied by the plethora of mutations in RNA-binding proteins
that are causative in similar pathologies (Li et al., 2013). Second,
in yeast and Drosophila model systems, mutations that disrupt
the RNA-binding ability of FUS or TDP-43 reduces or prevents
their toxicity (Daigle et al., 2013; Johnson et al., 2009; Sun
et al., 2011; Voigt et al., 2010). Similarly, mutations limiting
RNA binding suppress the toxicity of PABPN1, wherein an
alanine expansion underlies oculopharyngeal muscular dystro-
phy (Chartier et al., 2006). Third, in yeast or Drosophila, other
mutations that alter RNA physiology can enhance or suppress
the toxicity of pathogenic mutations. For example, overexpres-
sion of Pbp1, the yeast ortholog of Atx2, enhances TDP-43
toxicity in yeast and increases aggregates of RNA-binding
proteins (Swisher and Parker, 2010), whereas loss of Pbp1 sup-
presses TDP-43 toxicity and reduces stress granule formation
(Buchan et al., 2008; Elden et al., 2010). Analogous interactions
between the two proteins are also seen in the Drosophila eye
(Elden et al., 2010). The ataxin-2 and TDP-43 interaction is
probably significant to neurodegeneration because genetic
variants in both genes have been independently associated
with human ALS and because the two proteins colocalize in
stress granules as well as in pathological inclusion bodies
observed in patients (Bonini and Gitler, 2011). Similarly, muta-
tions in the orthologs of hnRNPA1 or hnRNPA2B1 in Drosophila
suppress the toxicity of pathogenic VCPmutations (Ritson et al.,
2010). Taken together, these observations argue that toxicity
in these conditions is caused by the formation of RNA-proteinaggregates. Thus, a critical question is why an increased load
of RNA-protein aggregates leads to toxicity?
Toxicity and Altered Ribostasis
We suggest that aberrant RNP aggregates are pathological,
at least in part, because they disrupt RNA homeostasis, or ‘‘ribo-
stasis.’’ We define ribostasis as the appropriate production and
regulation of the cellular transcriptome, which has downstream
effects on protein homeostasis. This is analogous to the concept
of protein-folding diseases in which age-dependent changes
in proteostasis contribute to some pathologies by saturating
proteostatic mechanisms, resulting in altered proteomes and a
variety of physiological changes that eventually result in cell
death (Balch et al., 2008; Douglas and Dillin, 2010; Garber,
2009; Kopito and Ron, 2000; Muchowski and Wacker, 2005;
Vij, 2011). Despite the parallels to proteostatic mechanisms,
ribostasis should be considered to be a distinct aspect of
cellular homeostasis for two reasons. First, the mechanisms
that underlie biogenesis, maturation, localization, translational
control, and degradation of RNA use distinct enzymatic and
molecular machinery. Second, cellular phenotypes and pathol-
ogies caused by alterations in ribostasis may have features
distinct from those caused by primary defects in mechanisms
of protein handling (see below).
Formation or persistence of mRNP aggregates is anticipated
to alter ribostasis by three different overlapping mechanisms,
which may synergize to trigger cell toxicity (Figure 2). First,
mRNP hyperaggregation could reduce the functional pool of
the mutated aggregation-prone mRNA-binding protein. Second,
by sequestering associated mRNAs, RNP aggregates could
alter the population of mRNAs available for translation. Third,
RNP aggregates could sequester other mRNA-binding regulato-
ry factors, including other mRNA-binding proteins, miRNAs,
and even noncoding RNAs, such that they are not available for
their normal functions. Sequestration ofmRNA regulatory factors
would be expected to alter the translation, localization, or decay
of many mRNAs and to also affect mRNA biogenesis. For
example, sequestration of the splicing factorMBNL1 into nuclear
RNP foci in myotonic dystrophies 1 and 2 results in alterations of
splicing (Fardaei et al., 2002; Mankodi et al., 2001; Miller et al.,
2000), and TDP-43 mislocalization can alter its own mRNA regu-
lation (Igaz et al., 2011). Thus, altered ribostasis can alter both
the biogenesis and function of mRNAs, potentially creating a
positive-feedback loop in which abnormal RNAs and altered pro-
tein production lead to more misregulation of cellular processes,
eventually leading to systemic inflammatory signaling and cell
death. In addition, aberrant mRNP aggregates are expected to
influence other aspects of RNA metabolism, as some of the
aggregated proteins (e.g., FUS or TDP-43) can be required for
transcription and/or small nuclear ribonucleic particles (snRNP)
assembly (Ishihara et al., 2013; Schwartz et al., 2012).
Aberrant mRNP aggregates are also likely to alter cell survival
by affecting signaling pathways. This is a possibility because
RNP aggregates can impact cell-signaling pathways that
mediate the cellular response to environmental inputs and/or
lead to cell death (Buchan and Parker, 2009; Thomas et al.,
2011). In addition, it is possible that the aberrant RNP aggregate
itself is sufficient to trigger a cellular response, which might leadCell 154, August 15, 2013 ª2013 Elsevier Inc. 731
to cell death. For example, progression of prion-disease-related
PrP pathology in mice requires phosphorylation of eIF2 (Moreno
et al., 2012), a translation initiation factor whose phosphorylation
triggers the accumulation of stress granules (reviewed in Buchan
and Parker, 2009). Any such alterations in cell signaling might
synergize with perturbation of ribostasis to trigger cell death.
Crosstalk betweenProtein-Folding andRNPAggregates
An important point is that there is crosstalk between mecha-
nisms that maintain proteostasis and ribostasis, which may
explain the clinical overlap in diseases associated with perturba-
tions of these two homeostatic mechanisms. For example,
muscles of patients with classic protein-aggregate myofibrillar
myopathies caused by mutations in Desmin or the chaperone
DNAJB6 contain cytoplasmic aggregates of the RNA-binding
protein TDP-43, a component of stress granules (Baloh, 2011;
Olive´ et al., 2009). Thus, secondary ribostasis defects may be
seen in cells primarily compromised by an increased misfolded
protein load. Such crosstalk could occur either due to the deple-
tion of cytoplasmic chaperones such as HSP70, which regulate
both protein and RNP aggregation in vivo (Gilks et al., 2004), or
through recruitment of misfolded domains to common aggre-
gates. An important corollary—that primary defects in ribostasis
should not only increase RNP aggregation but should also influ-
ence the protein-folding pathways—remains to be rigorously
tested, for instance, by examining the possible activation of
unfolded protein response following perturbations to RNA regu-
latory pathways.
Crosstalk between proteostasis and ribostasis is also evident
in the emerging role of autophagy in clearing RNP aggregates
from cells (Zhang et al., 2009; Buchan et al., 2013). Thus, it is
expected that impairment in autophagy through either age-
related decline or genetic mutation (e.g., VCP mutations) not
only perturbs proteostasis, but also disrupts the normal clear-
ance of stress granules, resulting in perturbed ribostasis. The
existence of these pathways emphasizes that some common
pathologies may arise through distinct trigger mechanisms and
indicates the need for caution in classifying neurodegenerative
diseases as arising from protein folding or mRNP assembly
defects based solely on limited characterization of inclusion
body pathology.
Why Cell-Type-Specific Degenerative Disease?
A prominent but enigmatic feature of age-related degenerative
diseases is cell-type-selective degeneration, with brain and
muscle most frequently affected. Moreover, individual diseases
have characteristic patterns of cell type involvement. For
example, ALS typically shows the greatest impact on motor neu-
rons of the frontal cortex, brainstem, and spinal cord, whereas
degeneration in FTLD is typically restricted to the cerebrum but
is spread over a broader area of cortex involving the frontal
and temporal lobes. Remarkably, these cell-type-selective
degeneration patterns persist even in dominantly inherited dis-
ease in which the mutant protein (e.g., TDP-43) is ubiquitously
expressed. Thus, an important question is why these defects in
RNP or protein-folding mechanisms have a disproportionate
impact on certain cells. And how and why do these show their
remarkable dependence on age? The answers to these ques-732 Cell 154, August 15, 2013 ª2013 Elsevier Inc.tions must lie in some of the unique properties of the vulnerable
cell types, which might relate to: (1) their longevity, (2) their un-
usual cell biology and cytoarchitecture, and (3) their connectivity
(Figure 3). One possibility is that, because neurons and muscle
cells are unusually long-lived cells, they may have increased
vulnerability to time-dependent accumulation of sublethal dam-
age. Whereas shorter-lived cells turn over before such damage
reaches a pathological level, perhaps longer-lived cells accu-
mulate age-related damage to pathological levels, resulting in
cellular dysfunction. Alternatively, nonneuronal cells may also
die in response to RNP or protein-folding defects but, because
they are efficiently replaced by stem cells, may not cause visible
organismal dysfunction.
The unusual cellular architecture of neurons and muscle, with
accompanying increased requirement for spatially restricted
gene expression, may also contribute to their selective vulnera-
bility. For example, neurons contain mRNP granules related to
stress granules and P bodies, both in the soma and at synapses
(Barbee et al., 2006). Moreover, components of these stress
granules are required for synaptic plasticity, at least in model
systems (Kwak et al., 2008; McCann et al., 2011). Neurons
also contain a related set of RNP granules referred to as neuronal
RNA transport granules, which deliver translationally repressed
mRNAs to synaptic sites in dendrites, where synaptic activity
promotes their localized translation (Batish et al., 2012; Holt
and Bullock, 2009). The translation of thesemRNAs at synapses,
presumably necessary for normal neuronal function, may place
unusual demands on local mRNA synthesis mechanisms to
maintain the synaptic proteome or respond to synaptic activity
(Cajigas et al., 2012). In addition, it is possible that retrograde
communication to the nucleus that arises from local translation
of synaptic mRNAs could mediate cell survival or cell mainte-
nance signaling (Lin and Holt, 2008). Consistent with a scenario
in which altered translational control promotes cell death by
blocking synaptically derived survival signals: (1) the SCA2-
associated, stress granule protein Atx2 is required for normal
translational control in Drosophila synapses (McCann et al.,
2011) and (2) synaptic degeneration has been found to precede
neuronal loss in systems in which this issue has been analyzed
(Mallucci, 2009; Selkoe, 2002). Likewise, in skeletal muscle cells,
the development and maintenance of certain specialized struc-
tures such as the postsynaptic neuromuscular junction and
possibly the contractile apparatus require spatial control of local
protein translation (Liu et al., 2012a; Sanes and Lichtman, 2001).
Finally, tissue degeneration that characterizes neurodegener-
ative disease is not solely cell autonomous and involves mecha-
nisms for tissue-wide spread of disease that may include the
dissemination of toxic aggregates between synaptically con-
nected neurons (Brundin et al., 2010; de Calignon et al., 2012;
Lee et al., 2010; Liu et al., 2012b), which might also contribute
to the sensitivity of the nervous system to degenerative diseases.
Altered Ribostasis: Looking Forward
The involvement of RNP assembly perturbations in neurodegen-
erative diseases highlights future directions. It will be critical
to understand how both normal and pathological RNP aggre-
gates are assembled, disassembled, and cleared in neurons
and muscle cells. Equally important will be understanding the
Figure 3. Three Models for the Selective Sensitivity of Neurons to Altered Ribostasis
(A) Neurons are long-lived cells and therefore accumulate more damage over their lifetimes. In addition, because they are not efficiently replaced by stem cells,
neuronal loss is more consequential that the death of a nonneuronal cell like a fibroblast.
(B) Neurons have higher levels of translationally repressed mRNAs than other cells, particularly in their dendrites and axons. They may therefore be more easily
tripped into a pathological state: either by being more responsive to aggregation-inducing conditions or by being more sensitive to altered RNA regulation.
(C) The connectivity of neurons may result in the enhanced spread of mRNP aggregates or cell death to neurons that are synaptically connected.relationship between the normal RNP assemblies and the
pathological aggregates that characterize end-stage disease.
Do the pathological inclusions in ALS, FTLD, IBM, and related
diseases evolve from normal RNP assemblies? In addition,
for analysis of human exome and genome sequences from
patients with familial and sporadic neurodegenerative disease,
genes encoding components of RNP granules or factors that
regulate their assembly, disassembly, or clearance should be
considered as candidate neurodegeneration susceptibility
genes, e.g., Buchan et al. (2013) andOhn et al. (2008). Identifying
disease-causative genes will offer new opportunities for diag-
nosis, which should improve the ability to predict patient-spe-
cific neurological symptoms and their rates of progression.
Finally, it will be important to explore the concept of directly
targeting RNP granule assembly, disassembly, or clearance as
a strategy of therapeutic intervention. Possible therapeutic
approaches include drugs that: (1) inhibit signaling/assembly
mechanisms that promote toxic aggregate formation, (2) acti-
vate mechanisms that antagonize aggregate formation, or (3)
promote clearance of toxic aggregates (Pandey et al., 2007),for instance by using drugs such as rapamycin to trigger a burst
of autophagy, which might have both prophylactic and thera-
peutic benefits.
An unresolved issue is how frequently perturbations in ribosta-
sis will be involved in other pathologies. Reports have described
the presence of RNA and RNA-binding proteins in aggregates
that form in prion disease, taupathies, and Alzheimer’s, raising
the speculation that many of these aggregates will be RNA-
protein assemblies (Ginsberg et al., 1998). Thus, an important
future direction will be to discern which diseases involve RNA
in the pathology and what those roles suggest for diagnostic
and therapeutic interventions.
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